Fig. 6

Cell viability assay. The impact of miRNA-34a on the growth of LLC (a, b) and 4T1 (c, d) cells was assessed following transfection with miRNA/ELPs. LLC or 4T1 cells (5 × 10³/well) in a 96-well plate were treated with negative control (NC) miRNA/ELPs and miRNA-34a/ELPs at concentrations ranging from 50 to 400 nM for 48 h. Cell proliferation was evaluated using a CCK assay. Specifically, 10 μL of CCK-8 solution was added to each well and incubated for 1 h at 37 ℃, and the change in absorbance was measured at a wavelength of 450 nm. One-way ANOVA was performed to assess the statistical significance of the differences among groups treated with miRNA/ELP complexes at different miRNA concentrations. *P < 0.05, NC miRNA/A86 vs. miRNA-34a/A86 (400 nM) delivery, and **P < 0.001, NC miRNA/Tat-A86 vs. miRNA-34a/Tat-A86-mediated miRNA (400 nM) delivery